Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 09:25 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Trial of Netarsudil for Acceleration of Corneal Endothelial Restoration
NCT03971357 · Price Vision Group · PHASE2/PHASE3 · terminated · last registry update 2023-02-06 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “variance of outcome measures was substantially greater than anticipated in the statistical plan” | – | Registry record, Price Vision Group |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against ROCK2 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2023-11-22Phase 3 first posted: Sanofi, Belumosudil + Placebo (NCT06143891)
- 2023-11-01Results posted on the registry: BioNova Pharmaceuticals (Shanghai) LTD., BN101 (NCT04930562)
- 2023-10-13Phase 3 first posted: Sanofi, Belumosudil + Azithromycin (NCT06082037)
- 2023-09-21Phase 3 first posted: Singapore Eye Research Institute, Ripasudil (NCT06048380)
- 2023-08-30Results posted on the registry: Kadmon, a Sanofi Company, Belumosudil (KD025) + Placebo (NCT03919799)
- 2023-08-30Also stopped (terminated): Kadmon, a Sanofi Company, Belumosudil (KD025) + Placebo (NCT03919799)
- 2023-06-28Results posted on the registry: Kadmon, a Sanofi Company, Belumosudil (KD025) (NCT02841995)
- 2023-06-05Results posted on the registry: Kadmon, a Sanofi Company, Belumosudil (NCT04680975)
- 2023-06-05Also stopped (terminated): Kadmon, a Sanofi Company, Belumosudil (NCT04680975)
- 2023-04-24Phase 3 first posted: Kowa Research Institute, Inc., Ripasudil + Placebo (NCT05826353)
- 2023-04-03Phase 3 first posted: Kowa Research Institute, Inc., Ripasudil + Placebo (NCT05795699)
- 2023-02-27Results posted on the registry: Aerie Pharmaceuticals, Netarsudil ophthalmic solution 0.02% + Ripasudil hydrochloride hydrate ophthalmic solution 0.4% (NCT04620135)
- 2022-12-21Phase 3 first posted: Wills Eye, Netarsudil 0.02% Ophthalmic Solution [RHOPRESSA] + Glycerin 0.2%/Hypromellose 0.2%/Peg 1%/Soln,Oph,Ud (NCT05660447)
- 2022-09-08Results posted on the registry: Kadmon Corporation, LLC, Belumosudil (NCT02688647)
- 2022-09-06Phase 3 first posted: Kowa Research Institute, Inc., Ripasudil + Placebo (NCT05528172)
- 2022-09-01Results posted on the registry: Aerie Pharmaceuticals, Netarsudil Ophthalmic + Netarsudil Ophthalmic (NCT04498169)
- 2022-03-31Also stopped (withdrawn): University of California, San Diego, a drug against ROCK2 (NCT04064918)
- 2022-03-24Also stopped (terminated): Sanofi, SAR407899 + Placebo (NCT03236311)
- 2022-03-21Phase 3 first posted: Stanford University, Topical Ripasudil + Topical Placebo (NCT05289661)
- 2022-03-11Phase 3 first posted: Stanford University, Ripasudil + Placebo (NCT05275972)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision